Paris based Sofinnova continues to invest in the Alzheimer’s fight, with a €27.5M pot given to Swiss Asceneuron (originally a spin-off from Merck-Serono). Sofinnova therefore joins other investors such as JJDC in the new and optimistic biotech wave of therapies for neurodegenerative diseases like Alzheimer’s and progressive supranuclear palsy (PSP).
The last decade has been fairly disappointing for researchers in the Neuro-degenerative disease field and investors alike, with various ACE-inhibitor programs from Roche and Eli Lilly proving to be dead in the water. However, a few exciting discoveries in the last couple of years has begun to revive the area, sparking of a real trend in the Biotech Industry (read our in-depth overview of therapies for Alzheimer’s here).
Sofinnova’s interest is clearly well founded in the fight against Alzheimer’s, who has formerly also invested Boehringer Ingleheim‘s Phase I nanobody candidate for the disease (using Ablynx’s Nanobody platform).